Business Description
N4 Pharma PLC
ISIN : GB00BYW8QM32
Description
N4 Pharma PLC is the holding company for N4 UK. N4 UK is a specialist pharmaceutical company engaged in the development of nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines. The company operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.94 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 23.1 | |||||
| 3-Year EPS without NRI Growth Rate | 20.6 | |||||
| 3-Year FCF Growth Rate | 20.6 | |||||
| 3-Year Book Growth Rate | -41.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 85.91 | |||||
| 9-Day RSI | 75.92 | |||||
| 14-Day RSI | 71.23 | |||||
| 12-1 Month Momentum % | -64.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 22.75 | |||||
| Quick Ratio | 22.75 | |||||
| Cash Ratio | 21.52 | |||||
| Days Sales Outstanding | 8455.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.1 | |||||
| Shareholder Yield % | -29.02 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -19683.33 | |||||
| Net Margin % | -18583.33 | |||||
| FCF Margin % | -16228.57 | |||||
| ROE % | -87.5 | |||||
| ROA % | -81.41 | |||||
| ROIC % | -586.16 | |||||
| 3-Year ROIIC % | 112.82 | |||||
| ROC (Joel Greenblatt) % | -1317.1 | |||||
| ROCE % | -90.45 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.83 | |||||
| EV-to-EBIT | -1.08 | |||||
| EV-to-EBITDA | -1.08 | |||||
| EV-to-Revenue | 211.05 | |||||
| EV-to-FCF | -0.99 | |||||
| Earnings Yield (Greenblatt) % | -93.03 | |||||
| FCF Yield % | -39.26 | |||||
| Forward Rate of Return (Yacktman) % | -1047.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
N4 Pharma PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.007 | ||
| EPS (TTM) (€) | -0.005 | ||
| Beta | 2.1 | ||
| Volatility % | 244.17 | ||
| 14-Day RSI | 71.23 | ||
| 14-Day ATR (€) | 0.000082 | ||
| 20-Day SMA (€) | 0.0032 | ||
| 12-1 Month Momentum % | -64.29 | ||
| 52-Week Range (€) | 0.001 - 0.015 | ||
| Shares Outstanding (Mil) | 394.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
N4 Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
N4 Pharma PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
N4 Pharma PLC Frequently Asked Questions
What is N4 Pharma PLC(STU:0GO)'s stock price today?
The current price of STU:0GO is €0.00. The 52 week high of STU:0GO is €0.02 and 52 week low is €0.00.
When is next earnings date of N4 Pharma PLC(STU:0GO)?
The next earnings date of N4 Pharma PLC(STU:0GO) is 2025-04-23 Est..
Does N4 Pharma PLC(STU:0GO) pay dividends? If so, how much?
N4 Pharma PLC(STU:0GO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers